Kornimate/medical-research-clean huggingface dataset:
effectiveness of two different body positions during facemask ventilation in obese patients

Conditions: Obesity

Summary: it is important to provide enough oxygen to the patients who are asleep during surgery. one way to do this is by using a mask placed over the face to help them breathe. when it becomes difficult getting enough oxygen into the patient's body using the mask, it's called difficult mask ventilation. there can be different reasons for this, and having a higher bmi is one of them. body physique is assessed by body mass index (bmi). this calculation gives an indication of a person's weight relative to their height. there is some evidence in the research literature to suggest that when the patient is positioned in a way that helps their airway, like using a device to lift their head and torso 25 degrees , it might help the process of getting enough oxygen work better. the study aims to determine if patients with high bmi can breathe better using a face mask while they are in a head elevated position compared to lying flat on their back.

facemask ventilation is an important technique applied by anesthesiologists after induction of general anesthesia and before tracheal intubation. it is also used as a rescue maneuver in situations where a patient's consciousness is compromised affecting oxygenation. obesity is well known to be one of the difficult predictors for facemask ventilation. in fact, the occurrence of difficult facemask ventilation is more frequent in obese patients than non obese. one of the maneuvers described to optimize the effectiveness of facemask ventilation in the general population is positioning the patient in a 25 degree head elevated position. a previous study has demonstrated improvement in facemask ventilation in obese patients with bmi from 30 to 40 kg/m2 in the head elevated position, compared to supine. however, it is not yet determined if this is applicable to patients with a bmi above 40 kg/m2. adult obese patients with bmi of at least 40 kg/m2 will be randomized to be ventilated after induction of general anesthesia via a face mask while in one of the positions: supine or head elevated, while the volume of air that enters and exits the lungs is measured. participants will then be changed to the second position, ventilated in the same manner and measures obtained again. do patients with class 3 obesity positioned in the head elevated position can be better ventilated with a face mask and positive pressure, compared to the supine position?

Eligibility criteria:
inclusion criteria: * bmi \> 40 kg/m2 * age \> 18 years * scheduled for elective surgery under general anesthesia * have the ability to comprehend the rationale for the study and provide consent exclusion criteria: * pregnancy, * risk of aspiration of gastric content * patients using glucagon-like peptide(glp)-1 agonists * emergency cases * upper airway disease or airway anatomical abnormalities * presence of major cardiovascular, respiratory, or cerebral vascular disease * if the provider anesthesiologist indicates an awake technique to secure the airway
stop emergency room visits for hyperglycemia project - district of columbia (dc)

Conditions: Type 2 Diabetes Mellitus

Summary: to demonstrate that a focused emergency department (ed) intervention for uncontrolled hyperglycemia enables safe and effective glycemic management and reduces emergency room re-visits. we assessed hypoglycemia bg \< 60mg/dl; change in mean blood glucose and a1c, and ed revisits for hyperglycemia.

patients with bg \> 200mg/dl presenting to an urban tertiary care hospital ed were enrolled in a 4 week prospective intervention with historic self-controls. subjects returned at 12-72 hours, 2 and 4 weeks. diabetes medications (including sulfonylureas, metformin and/or insulin) were initiated and/or adjusted at each visit using the intervention algorithm per presenting blood glucose and prior diabetes medications. survival skills self-management education and navigation to outpatient services were provided.

Eligibility criteria:
inclusion criteria: * age \> 18 years * type 2 diabetes mellitus, * random bg \> 200 mg/dl, * willing and able to provide informed consent and to participate in diabetes self-management education (dsme) * stable for discharge from the ed once hyperglycemia treatment initiated. exclusion criteria: * type 1 diabetes mellitus, * diabetic ketoacidosis or hyperosmolar non-ketotic state, * concomitant treatment with glucocorticoids (other than stable maintenance dose therapy), * cognitive or physical impairment preventing participation in dsme * unwillingness or inability to provide consent and/or attend follow-up visits.

Keywords: type 2 diabetes mellitus uncontrolled hyperglycemia emergency department
comparison of effect of postoperative cyclosporine a 2% ophthalmic emulsion and betamethasone eye drop on surgical success of trabeculectomy procedure

Conditions: Glaucoma, Open Angle

Summary: glaucoma is one of the leading causes of blindness worldwide and trabeculectomy is the most commonly performed operation to slow-down the disease progression. in this study, we compare the effect of topical cyclosporine a and betamethasone eye drops on the postoperative course and surgical success of trabeculectomy.

trabeculectomy is still the most popular filtering surgery for glaucomatous patients. in this type of surgery, postoperative care and management is highly important for surgical success. a principle component of postoperative regimen is anti-inflammatory medications. however, corticosteroid eye drops, the most frequently used agents, have some side effects, including raising intraocular pressure. cyclosporine a could be an interesting alternative, because not only it has acceptable anti-inflammatory effect and could reduce some ocular surface problems, but also it has minimal direct effect on intraocular pressure. in this study, we will compare the effect of topical cyclosporine a and betamethasone on surgical outcome and postoperative course of trabeculectomy patients. the study is a prospective study to compare the effect of topical betamethasone and cyclosporine a on postoperative findings of glaucoma patients, undergoing trabeculectomy surgery. in this study, trabeculectomy patients, who fulfill the study criteria, will be randomized to either study group and follow-up visits will be done in a masked fashion. in each visit, a detailed history taking and eye examination will be done by an examiner unaware of study group. a third party would do data control for patient safety. at the conclusion of the study, the data of the two groups would be compared. all human research ethical codes are strictly respected and the ethical committee of the university has an ongoing inspection on all study steps. we hypothesize that cyclosporine a could provide better inflammation and intraocular pressure control and may enhance surgical success rate. however, our null hypothesis is that the result in study groups will not differ statistically significantly.

Eligibility criteria:
inclusion criteria: * poag patient with insufficient iop control on maximal tolerable medical therapy (mtmt), undergoing primary trabeculectomy with mmc augmentation. exclusion criteria: * age \<20 years * history of previous ocular surgery in the same eye; * candidate for combined surgery; * pregnancy; * breast feeding; * monocular subject; * allergy to any topical antiglaucoma medication or cyclosporine

Keywords: glaucoma trabeculectomy cyclosporine betamethasone
alx-0061 phase i bioavailability study in healthy volunteers

Conditions: Rheumatoid Arthritis

Summary: the overall aims of the study are: * to assess the bioavailability of single doses of alx-0061, administered s.c. at three dose levels, using 2 corresponding single i.v. dose levels as reference. * to provide additional information on pharmacokinetics and pharmacodynamics of alx-0061. * to further determine the safety and tolerability of alx-0061. * to further evaluate the systemic (serum) immunogenicity of alx-0061.


Eligibility criteria:
key inclusion criteria: 1. healthy volunteers. 2. gender: male or female. 3. age 18 to 55 years. 4. body mass index (bmi): 18.0 ≥ bmi \< 30.0 kg/m2. key exclusion criteria: 1. any active inflammatory condition, or autoimmune disorder such as lupus erythematosus, multiple sclerosis or rheumatoid arthritis (ra). 2. any current or recent (within 4 weeks prior to dose) signs or symptoms of infection that requires parenteral antibiotic administration. 3. symptomatic infection, or suspicion thereof in the last 1 week prior to dosing.
circular cyclocoagulation using hifu with eyeop1 device in glaucoma patients

Conditions: Glaucoma

Summary: the aim of the study is to evaluate the effectiveness and the safety of the cyclocoagulation using hifu in glaucoma patients


Eligibility criteria:
inclusion criteria: * primary open-angle glaucoma included pseudo-exfoliative glaucoma and pigmentary glaucoma * iop \> 21 mm hg on glaucoma medications, and indicated for filtering glaucoma surgery * patient must be aged 18 years and more * no previous cyclophotocoagulation procedure in the eye * no previous laser treatment in the eye during the 3 months before hifu procedure exclusion criteria: * history of previous glaucoma surgery with implantation of glaucoma drainage device in the study eye * history of ocular or retrobulbar tumor * retinal detachment, choroidal hemorrhage or detachment * ocular infectious diseasee within 14 days before hifu procedure

Keywords: glaucoma cyclocoagulation hifu - high intensity focused ultrasound ciliary body
cied infection quality initiative demonstration project

Conditions: Infections

Summary: the aim of this quality initiative (qi) demonstration project is to develop a model to increase guideline-driven care for patients with cardiovascular implantable electronic devices (cied) infection. multidisciplinary teams will be established to carry out the multifaceted intervention. this program seeks to improve early identification and diagnosis, appropriate treatment, and faster time to treatment of cied infection.

retrospective data will be collected pre-intervention. the interventions will then be implemented for a total of six months and will continue through the data collection period. prospective data collection will start three months after the intervention is started and will continue for a total of 12 months.

Eligibility criteria:
inclusion criteria: * age ≥18 years * cardiovascular implantable electronic device (cied) in place * presumed cied infection, as defined by: 1. positive blood culture (two or more positive blood cultures for typical skin organisms (coagulase-negative staphylococci, corynebacterium species, propionobacterium species), or one positive blood culture for all other microorganisms), with no other source identified to explain the bacteremia 2. cases with definite evidence of pocket infection (defined as localized erythema, swelling, pain, tenderness, warmth, erosion, or drainage), if treated with antibiotics before culture, even with negative culture, will be considered device infection exclusion criteria: * patients who are inappropriate for device extraction, for example those who are dnar and not using therapy to prolong survival because any procedure is considered inappropriate and/or it is unlikely that extraction would change overall prognosis * death within one week of definitive cied systemic infection diagnosis or positive blood culture. cases of bacteremia originating from a source other than the cied that resolve without any evidence of cied involvement should not be considered as cied infection * patients with left ventricular assist devices (lvads)

Keywords: cardiac implantable electronic devices quality improvement
the effect of treatment zone decentration on axial length elongation after orthokeratology

Conditions: Myopia; Orthokeratology

Summary: orthokeratology lens is an effective method for myopia control. this study analyzed the effects of treatment zone decentration on axial length elongation in adolescents with orthokeratology lens.

orthokeratology lens is an effective method for myopia control. this study aimed to investigate the effects of treatment zone decentration on axial length elongation in adolescents with orthokeratology lens in 1 year. other factors that may affect axial growth were also analyzed.

Eligibility criteria:
inclusion criteria: * age from 8 to 15years * spherical equivalent(se) was range from -1.00d to -5.00d * conform to the standard of wearing orthokeratology lens exclusion criteria: * ocular diseases and systemic diseases * stop wearing for ≥7 days for any reason during the follow-up period * keratoconjunctival complications, glare, diplopia, or any other symptoms during follow-up

Keywords: myopia orthokeratology axial length decentration
factors affecting the difficulty of laparoscopic d2 lymph node dissection for gastric cancer

Conditions: Surgery-Complications

Summary: laparoscopic d2 lymph node dissection (lnd) for gastric cancer has a wide range of operations and a high degree of difficulty.the purpose of this study was to evaluate the relationship between clinicopathological factors and the difficulty of laparoscopic d2 lnd.


Eligibility criteria:
inclusion criteria: 1. all patients undergoing laparoscopic surgery 2. laparoscopic system is 2d and has complete d2 lymph node dissection. exclusion criteria: 1. patients undergoing laparotomy 2. incomplete video or clinicopathological information
effect of veramyst on the nasal and ocular symptoms of the early reaction to nasal challenge with allergen

Conditions: Allergic Rhinitis

Summary: the purpose of this study is to help us to a better understanding of how nose and eye symptoms are related in patients with allergies.


Eligibility criteria:
inclusion criteria: 1. males and females between 18 and 45 years of age. 2. history of grass and/or ragweed allergic rhinitis. 3. positive skin test to grass and/or ragweed antigen. 4. positive response to screening nasal challenge. exclusion criteria: 1. physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease. 2. pregnant or lactating women. 3. upper respiratory infection within 14 days of study start.
effects of nava and psv to aecopd patients' air distribution and dead space

Conditions: Chronic Obstructive Pulmonary Disease

Summary: chronic obstructive pulmonary disease(copd) is a common disease among people. acute exacerbation of chronic obstructive pulmonary disease(aecopd) is the acute and aggravating phase of copd which may lead to respiratory failure. mechanical ventilation is a very important therapy for those patients,but traditional ventilation modes have some defects, so investigators need to find new modes to solve these problems. in this study, the investigators compare neurally adjusted ventilatory assist (nava) and psv to observe the effects on aecopd patients' air distribution and dead space to determine if nava is a more appropriate ventilation mode for aecopd patients.


Eligibility criteria:
inclusion criteria: * aecopd patients who need invasive mechanical ventilation * patients who can tolerate assist mechanical ventilation * patients who have signed icf exclusion criteria: * patients who are younger than 18 years old or older than 75 years old * patients whose respiratory center is severely inhibited * patients who can not stand nava gastric tube * patients who have coagulation disorders * patients whose vital signs are unstable * patients who are in other clinical trails
leptin and liver enzymes responses to aerobic training in hepatitis c patients

Conditions: Hepatitis C

Summary: exercise is one of the most vital components of health maintenance. exercising regularly maintains the cardiovascular system health, promotes the health of liver, and declines the risks of complications induced by chcv. since overweight is the main risk factor for ir and type 2 dm which may speed the liver disease progression among hcv patients, exercise is very important for maintenance and loss of weight. further, exercise can relieve the side effects of medications of hcv, improve immunity, promote a sense of well-being, reduce levels of chronic fatigue, improve blood oxygen levels and increase the endorphins excretion which makes the patients fully energized (elgendi, shebl a, sliem m, and gary fa, 2018). studies on exercise effect in patients with chcv are quite scarce (de sousa fernandes et al., 2019). decreased leptin levels by exercise positively modulate insulin signaling and inhibit pathology progression (anaruma et al., 2019). since studies investigated physical activity effect on regulating hcv related leptin levels are very little, the present study aimed to explore the response of serum leptin and liver enzymes to aerobic exercise in nondiabetic overweight men with chcv.

the study group (n=20) received three sessions of aerobic walking exercise per week for 3 months. every session was done on an electronic treadmill with no inclination started with 5 minutes warm-up then 30 minutes of moderate-intensity aerobic training with 60-75% of target heart rate then followed or ended by 5 minutes cool down. the control group (n=20) will receive no training.

Eligibility criteria:
inclusion criteria: * men with hepatitis c patients at least from 6 months * bmi ranged ≥ 25 to \< 30 kg/m2. * fasting blood glucose level (fbg) \< 100 mg/dl. * waist circumference \< 102 cm. exclusion criteria: * besides the excluded individuals who participated in any form of physical training in the last 6 months, excluded patients by a physician will be patients with acute or other hepatitis types, cirrhotic or hepatocellular carcinoma, renal or respiratory problems, cardiovascular and neurologic diseases, and hypertension
gabapentin and oxcarbazepine for chronic neuropathic pain in children and adolescents: a clinical effectiveness study

Conditions: Pediatric Chronic Neuropathic Pain

Summary: given the widespread use of anticonvulsants in the pediatric chronic pain population and the absence of scientific data supporting their use, the investigators propose a randomized, double blind, two group parallel design in which a broad group of children and adolescents with chronic neuropathic pain would be randomized to receive either gabapentin or oxcarbazepine. the primary aim of the study is to assess the frequencies of successful treatment of pediatric patients with neuropathic pain treated with either gabapentin or oxcarbazepine. the primary hypotheses are as follows: hypothesis i: both gabapentin and oxcarbazepine will result in significant reduction in pain scores when compared to each patient's baseline. hypothesis ii: patients who continue on active drug (gabapentin or oxcarbazepine) during the second phase of the trial will report greater pain reduction relative to baseline than patients who are randomized onto placebo at this randomization point. secondary aims of the study are to compare groups treated initially with gabapentin or oxcarbazepine with regard to reduction in pain scores (both at rest and with evoked maneuvers), functional disability scores, tolerability, and measures of mood and cognitive functioning. secondary hypotheses are that gabapentin and oxcarbazepine differ in their effects on: 1. pain scores at rest and with evoked maneuvers 2. functional disability scores 3. tolerability (frequencies of side-effects) 4. depression and anxiety scales 5. neuropsychological measures of cognitive processing speed, working memory, and attention.


Eligibility criteria:
inclusion criteria: 1. patients between the ages of 8 and 18 at the time of the study with history of chronic (lasting ≥ 4 weeks) neuropathic pain that includes a known injury to a peripheral nerve and/or a pattern of pain responses that includes allodynia, burning, paresthesias or dysesthesias will be included in this study, provided that informed consent has been given by parents. 2. patient's whose pain rates between moderate to severe at the time of inclusion (ranging from 4-10 in a numeric pain rating scale) 3. eligible diagnoses include complex regional pain syndrome, fibromyalgia, lumbar radiculopathy, spinal cord injury, erythromelalgia, small fiber neuropathies, traumatic or post-surgical peripheral nerve or plexus injuries, and extremity pain with severe pain to light touch (allodynia). 4. child has age-appropriate spoken and written knowledge of english. 5. parent may be able to utilize an interpreter if need be. exclusion criteria: 1. unstable psychiatric illness (suicidal ideation, disorganized behavior) 2. uncontrolled seizure disorder 3. chronic headaches only 4. abdominal pain only 5. prior experience with anticonvulsants for pain treatment. 6. patients with syndrome of inappropriate secretion of antidiuretic hormone
the integrated support and palliative in cancer day-care hospital for patients with advanced cancers: impact on quality of life, care pathways and support for caregivers (hdj-spi)

Conditions: Cancer, Advanced

Summary: the main objective is to show the impact on the quality of life (qol) for adults patients with advanced cancer managed in day hospital of integrated palliative care of cancer center (hdj-spi).


Eligibility criteria:
inclusion criteria: 1. patient ≥ 18 years old with advanced solid tumor 2. addressed for the first time to the palliative care team according to current criteria (medico-psycho-social symptoms, progressive risks) 3. with or without anti-cancer treatment 4. with estimated life expectancy of more than 2 months and less than 12 months 5. able to communicate in french and answer questionnaires 6. affiliated with a social security system 7. having signed informed consent, co-signed by the partner if designated by the patient exclusion criteria: 1. patient with primitive brain tumor or malignant hemopathy 2. severe psychopathological disorders 3. pregnant patient or childbearing potential without effective method of birth control 4. unable to be followed at the cancer center until death 5. patient deprived of liberty or under guardianship -
"pharmacoepidemiological evaluation of autophagy inhibition in treatment of hcv patients resistant to standard therapy. pilot study"

Conditions: Hepatitis C Virus

Summary: the purpose of this study is to assess the efficacy of chloroquine comparing with placebo for treatment of non- response hcv patients.. in this triple blind pilot study, 20 patients with confirmed chronic hepatitis c will be randomize into treatment group (chloroquine 150 mg daily, for 8 weeks) or control group (placebo once daily, for 8 weeks). patients who have receiving anti neoplastic, anti viral or immunomedullator drugs during 6 months prior to study, have co-infection hepatitis a,c,d or hiv, severe liver or renal dysfunction, are pregnant or breast fed, or refuse to sign informed consent will be excluded.. at the end of therapy (12 weeks) and at baseline, first, second and third month after receiving drug and placebo hcv virus load, cbc lft and biochemical parameters will be evaluated and compared between groups.


Eligibility criteria:
inclusion criteria: * patients who failed to achieve a decline of 2 log hcv rna iu/ml after 12 weeks of treatment * who never achieved undetectable hcv rna during treatment of a minimum duration of 24 weeks exclusion criteria: * receiving anti neoplasm, anti viral or immunomedulator drugs during 6 months prior to study * coinfection with hepatitis a,c,d viruses or hiv * severe dysfunction of liver and kidney * pregnancy * breast feeding * refusing to give informed consent * active alcohol user * presence of decompensate cirrhosis